Article Sidebar

Submitted
May 22, 2023
Published
December 23, 2023
Download
PDF
Statistic
Read Counter : 438 Download : 1

Main Article Content

Abstract

Tuberculosis, caused by infection with Mycobacterium tuberculosis, is still a global concern. The existence of resistance to the first line of anti-TB, namely isoniazid and rifampicin, is an urgent need for the development of new drugs that are effective and safe against tuberculosis. Bedaquiline has received approval from the FDA as a new anti-TB drug discovered to treat drug-resistant tuberculosis. This article aims to review the role of bedaquiline in the treatment of drug-resistant tuberculosis mechanisms, evidence, effectiveness, and adverse events. This narrative review uses a literature study approach by identifying various literature and research articles through databases as relevant references. Bedaquililine belongs to the diarylquinoline class inhibits ATP-synthase activity and suppresses the growth of active and dormant mycobacteria. Various clinical trials conducted previously have evaluated the use of bedaquiline-based regimens for the treatment of adults with drug-resistant tuberculosis. Bedaquiline-based regimens showed efficacy and were generally well tolerated in numerous studies. Currently, further evaluation is needed regarding its efficacy, safety, and tolerability in drug-resistant tuberculosis patients in Indonesia.

 

Keywords

Bedaquiline mechanism resistance tuberculosis antimicrobial

Article Details

Author Biography

Yulistiani Yulistiani, Universitas Airlangga Surabaya

Departemen Farmasi Klinik

References

  1. Ardhianto, D., Suharjono, Soedarsono, and Fatmawati, U., 2020, Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients, Journal of Basic and Clinical Physiology and Pharmacology, 32(4), 421-427.
  2. Bahuguna, A., dan Rawat, D. S., 2020, An overview of new antitubercular drugs, drug candidates, and their targets. Medicinal research reviews, 40(1), 263-292.
  3. Belosludtsev, K. N., Belosludtseva, N. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Agafonov, A. V., Lyubov, L. P dan Dubinin, M. V., 2019, Effect of bedaquiline on the functions of rat liver mitochondria. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1861(1), 288-297.
  4. Chahine, E.B., Karaoui, L.R., dan Mansour, H., 2014, Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Annals of Pharmacotherapy, 48(1), 107-115.
  5. Cholo, M.C., Mothiba, M.T., Fourie, B., dan Anderson, R., 2016, Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. Journal of Antimicrobial Chemotherapy, 72: 338–353.
  6. Cohen, K., dan Maartens, G., 2019, A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. Expert opinion on drug safety, 18(10), 875-882.
  7. Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., ... dan Spigelman, M., 2022), Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. New England Journal of Medicine, 387(9), 810-823.
  8. Darmayani, I.G.A.A.P.S., Ascobat, P., Instiaty, I., Sugiri, Y.J.R., dan Sawitri, N., 2022, Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data. Acta Medica Indonesiana, 54(3), 389-396.
  9. Deshkar A.T., dan Shirure P.A., 2022, Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis, Cureus, 14(8), 1-7.
  10. Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., dan Naidoo, K., 2018, Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. Journal of Antimicrobial Chemotherapy, 73(5), 1138-1151.
  11. Gaida, R., Truter, I., dan Peters, C. A., 2020, Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis, Southern African Journal of Infectious Diseases, 35(1) : 1-6.
  12. Hatami, H., Sotgiu, G., Bostanghadiri, N., Abadi, S.S.D., Mesgarpour, B., Goudarzi, H., Migliori, G.B. dan Nasiri, M.J, 2022, Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Jornal Brasileiro de Pneumologia, 48.
  13. JEMM, 2020, The Republic of Indonesia Joint External Monitoring Mission for Tuberculosis, JEMM, 30.
  14. Katrak, S., Lowenthal, P., Shen, R., True, L., Henry, L., dan Barry, P., 2021, Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 23.
  15. Kemenkes RI, 2020, Pedoman Nasional Pelayanan Kedokteran Tatalaksana Tuberkulosis, Kementrian Kesehatan Republik Indonesia, 44-65.
  16. Kempker, R. R., Mikiashvili, L., Zhao, Y., Benkeser, D., Barbakadze, K., Bablishvili, N., Avaliani, Z., Peloquin, C.A., Blumberg, H.M. dan Kipiani, M., 2020, Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline-or delamanid-containing regimens. Clinical Infectious Diseases, 71(9), 2336-2344.
  17. Khoshnood, S., Goudarzi, M., Taki, E., Darbandi, A., Kouhsari, E., Heidary, M., Motahar, M. Moradi, M. dan Bazyar, H, 2021, Bedaquiline: Current status and future perspectives. Journal of global antimicrobial resistance, 25: 48-59.
  18. Li, Y., Sun, F., dan Zhang, W., 2018, Bedaquiline and delamanid in the treatment of multidrugâ€resistant tuberculosis: Promising but challenging. Drug development research, 80(1), 98-105.
  19. Lyons, M. A., 2022, Pharmacodynamics and bactericidal activity of bedaquiline in pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy, 66(2), e01636-21.
  20. Martín-García, M., dan Esteban, J. (2021). Evaluating bedaquiline as a treatment option for multidrug-resistant tuberculosis. Expert Opinion on pharmacotherapy, 22(5), 535-541.
  21. Miotto, P., Zhang, Y., Cirillo, D. M., dan Yam, W. C., 2018, Drug resistance mechanisms and drug susceptibility testing for tuberculosis. Respirology, 23(12), 1098-1113.
  22. Pai, H., Ndjeka, N., Mbuagbaw, L., Kaniga, K., Birmingham, E., Mao, G., Alquier, L., Davis, K., Bodard, A., Williams, A., Tongel., M.V., Thoret‑Bauchet, F., Omar, S.V. dan Bakare, N., 2022, Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infectious Diseases, 22(1), 870.
  23. Patel, H., Pawara, R., Pawara, K., Ahmed, F., Shirkhedkar, A., dan Surana, S., 2019, A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity, Tuberculosis, 117, 79-84.
  24. Pezzella A.T., 2019, History of Pulmonary Tuberculosis, Thoracic Surgery Clinics, 29(1), 1-17.
  25. Pontali, E., Sotgiu, G., Tiberi, S., D'Ambrosio, L., Centis, R., dan Migliori, G. B., 2017, Cardiac safety of bedaquiline: A systematic and critical analysis of the evidence, European Respiratory Journal, 50.
  26. Pym, A. S., Diacon, A. H., Tang, S. J., Conradie, F., Danilovits, M., Chuchottaworn, C., Vasilyeva, I., Andries, K., Bakare, N., Marez, T.D., Theeuwes, M.H., Lounis, N., Meyvisch, P., Baelen, B.V., Heeswijk, R.P.G. dan Dannemann, B., 2016, Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis. European Respiratory Journal, 47(2), 564-574.
  27. Saeed, D. K., Ashraf, J., Hasan, Z., Shakoor, S., Kanji, A., & Hasan, R., 2022, Bedaquiline resistant Mycobacterium tuberculosis clinical isolates with and without rv0678 mutations have similar growth patterns under varying BDQ drug pressure. Tuberculosis, 137
  28. Sarathy, J. P., Gruber, G., dan Dick, T., 2019, Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline, Antibiotics, 8(4), 261.
  29. Singh, V., dan Chibale, K., 2021, Strategies to combat multi-drug resistance in tuberculosis. Accounts of chemical research, 54(10), 2361-2376.
  30. Singh, R., Kumar, R., & Kushwaha, S.P., 2021, Use of bedaquiline as a novel antitubercular agent in patient with multidrug˗ resistant tuberculosis–A review. Indian Journal of Healthcare, Medical & Pharmacy Practice, 2(1), 25-28.
  31. Taune, M., Ustero, P., Hiashiri, S., Huang, K., Aia, P., Morris, L., Main, S., Chan,G., Cros, P.D. dan Majumdar, S. S., 2019, Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Public Health Action, 9, S73.
  32. WHO, 2020, Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, World Health Organization, WHO, 4.
  33. WHO, 2020, WHO operational handbook on tuberculosis Module 4: Treatment – drug-susceptible tuberculosis treatment, World Health Organization.
  34. WHO, 2022, Global Tuberculosis Report 2022, World Health Organization, WHO, 13.
  35. WHO. 2022, WHO operational handbook on tuberculosis Module 5: management of tuberculosis in children and adolescents: World Health Organization.
  36. Worley, M. V., dan Estrada, S. J., 2014, Bedaquiline: a novel antitubercular agent for the treatment of multidrugâ€resistant tuberculosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 34(11), 1187-1197.
  37. Zimenkov, D.V., Nosova, E.Y., Kulagina, E.V. Antonoya, O.V., Arslanbaeva, L.R., Isakova, A.I., Krylova, L.Y., Peretokina, I.V., Makarova, M.V., Safonova, S.G., Borisov, S.E. dan Gryadunov, D.A. Examination of bedaquilineand linezolid-resistant Mycobacteriumtuberculosis isolates from the Moscow region. Journal Antimicrobial Chemotherapy, 72, 1901–1906.